Current Treatment Insights
Understand Today’s Standard of Care, Prepare for Tomorrow
Our treatment landscape assessments map how patients move through existing therapies and how treatment patterns shape market dynamics. Our treatment landscape analysis includes various current approved and off-label therapies, their respective doses, durations, efficacy, and safety benchmarks. We also provide the use of treatments by a line of therapy, and their KOL-perceived advantages and disadvantages. In addition, an in-depth assessment of patient characteristics, diagnosis, comorbidities, and their treatment, including treatment switches, polypharmacy, compliance, and persistence, is conducted.
What We Provide:
- Current Standard of Care (SoC) across 7MM & emerging markets
- Treatment Algorithm Mapping across major markets
- Physician Practice Pattern Insights
- Therapy-Class & Brand-Level Benchmarking
- Efficacy, Safety, Dosing & Differentiation Analysis
- Real-World Utilization Trends (switching, persistence, adherence)
- Pipeline vs. Standard-of-Care Gap Analysis
How It Helps You:
- Identify commercial white spaces
- Understand why physicians choose certain therapies (differentiation points)
- Benchmark products vs. competitors
- TPP design
- Refine global and local launch strategies
What Strategic Answers Clients Will Receive:
- What are physicians currently prescribing, and why?
- How do treatment algorithms differ across geographies and clinical settings?
- Which therapies dominate the market, and what factors drive their adoption?
- What are the real-world utilization patterns (switching, adherence, persistence)?
- Where are the gaps, dissatisfaction areas, or pain points with current treatment options?
- How can new therapies position themselves relative to today’s standard of care?
Reports:
Market Access and Reimbursement Insights
Thelansis’s “Hemophilia Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.
Emerging Therapy, Unmet Needs and TPP Insights
Thelansis’s “Hemophilia Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Market Access and Reimbursement Insights
Thelansis’s “Neuroblastoma (NB) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.
Emerging Therapy, Unmet Needs and TPP Insights
Thelansis’s “Neuroblastoma (NB) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Market Access and Reimbursement Insights
Thelansis’s “Chronic Spontaneous Urticaria (CSU) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.
Emerging Therapy, Unmet Needs and TPP Insights
Thelansis’s “Chronic Spontaneous Urticaria (CSU) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Need customize support?
Thelansis also caters to your specific needs by providing customized reports that satisfy your organizational requirements. Get on-demand customization of the report’s scope to exactly meet your needs.

